C. Mormont

428 total citations
13 papers, 324 citations indexed

About

C. Mormont is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C. Mormont has authored 13 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in C. Mormont's work include Lung Cancer Treatments and Mutations (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Circadian rhythm and melatonin (2 papers). C. Mormont is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Circadian rhythm and melatonin (2 papers). C. Mormont collaborates with scholars based in Canada, France and United States. C. Mormont's co-authors include Martin G. Myers, Sidney Chocron, David E. Johnstone, Richard Baillot, Pierre Martineau, Jean L. Rouleau, Wiek H. van Gilst, Wayne Warnica, James Waterhouse and Simon Folkard and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

C. Mormont

12 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Mormont Canada 7 107 98 97 50 50 13 324
P Giraud France 8 34 0.3× 112 1.1× 47 0.5× 13 0.3× 54 1.1× 28 378
HS Randeva United Kingdom 11 33 0.3× 52 0.5× 45 0.5× 65 1.3× 3 0.1× 21 474
J Dupont France 7 78 0.7× 185 1.9× 39 0.4× 14 0.3× 39 0.8× 12 397
Christian Lillelund Denmark 12 347 3.2× 132 1.3× 44 0.5× 71 1.4× 31 0.6× 16 538
S. F. Smith United Kingdom 10 17 0.2× 71 0.7× 16 0.2× 96 1.9× 8 0.2× 25 341
J Schmerber Belgium 12 83 0.8× 279 2.8× 24 0.2× 23 0.5× 5 0.1× 25 353
Benjamin V. Tran United States 7 52 0.5× 65 0.7× 66 0.7× 51 1.0× 3 0.1× 11 274
Xiaohong Luo China 9 85 0.8× 35 0.4× 17 0.2× 60 1.2× 4 0.1× 23 329
Andrey Marusin Russia 7 24 0.2× 15 0.2× 43 0.4× 96 1.9× 8 0.2× 32 355
Virgil S. Lucas United States 8 135 1.3× 33 0.3× 65 0.7× 65 1.3× 6 0.1× 12 422

Countries citing papers authored by C. Mormont

Since Specialization
Citations

This map shows the geographic impact of C. Mormont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Mormont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Mormont more than expected).

Fields of papers citing papers by C. Mormont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Mormont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Mormont. The network helps show where C. Mormont may publish in the future.

Co-authorship network of co-authors of C. Mormont

This figure shows the co-authorship network connecting the top 25 collaborators of C. Mormont. A scholar is included among the top collaborators of C. Mormont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Mormont. C. Mormont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Mormont, C. & David N. Weisstub. (2020). Death and dying: From assisted suicide to COVID-19 and back. Ethics Medicine and Public Health. 14. 100527–100527.
2.
Allo, Ghassan, Xiaoduan Weng, Lucia Kim, et al.. (2013). Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.. Journal of Clinical Oncology. 31(15_suppl). 6041–6041. 5 indexed citations
3.
Razak, A.R. Abdul, Denis Soulières, Scott A. Laurie, et al.. (2012). A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology. 24(3). 761–769. 82 indexed citations
4.
Tourneau, C. Le, Eric Winquist, Sébastien J. Hotte, et al.. (2010). Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 28(15_suppl). 5531–5531. 13 indexed citations
5.
Ahlgren, P.D., Michael P. Thirlwell, Ruth O’Regan, et al.. (2009). An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). e12019–e12019. 2 indexed citations
6.
Rouleau, Jean L., Wayne Warnica, Richard Baillot, et al.. (2007). Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery. Circulation. 117(1). 24–31. 105 indexed citations
7.
8.
Minors, David, Torbjörn Åkerstedt, Greg Atkinson, et al.. (1996). The Difference Between Activity When in Bed and Out of Bed. I. Healthy Subjects and Selected Patients. Chronobiology International. 13(1). 27–34. 64 indexed citations
9.
Mormont, C., et al.. (1996). The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).. PubMed. 24(1). 77–81. 13 indexed citations
10.
11.
Thomas, Frédéric, C. Mormont, & B. Morgan. (1994). Gastrin-releasing peptide antagonists. Drugs of the Future. 19(4). 349–349. 5 indexed citations
12.
Prévost, Grégoire, et al.. (1993). Therapeutic use and Perspectives of Synthetic Peptides in Oncology. Acta Oncologica. 32(2). 209–215. 12 indexed citations
13.
Mormont, C., et al.. (1970). [A long-acting neuroleptic. 3. Pilot study of penfluridol (R 16341)].. PubMed. 70(4). 523–51. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Giraud Breakdown of academic impact, for papers by HS Randeva Breakdown of academic impact, for papers by J Dupont Breakdown of academic impact, for papers by Christian Lillelund Breakdown of academic impact, for papers by S. F. Smith Breakdown of academic impact, for papers by J Schmerber Breakdown of academic impact, for papers by Benjamin V. Tran Breakdown of academic impact, for papers by Xiaohong Luo Breakdown of academic impact, for papers by Andrey Marusin Breakdown of academic impact, for papers by Virgil S. Lucas
Rankless by CCL
2026